Public Release: 

World's bone health research experts gather Sept. 28-Oct. 1, Montreal

Announcement of new clinical recommendations to prevent osteoporotic fractures, latest research on osteoporosis drug "holidays," unexpected fracture risk in men, and elevated hip fracture risk with type-2 diabetes


More than 3,000 bone scientists will come together for the American Society for Bone and Mineral Research (ASBMR) 2018 Annual Meeting in Montréal September 28 - October 1, the premier scientific meeting in the world on bone, mineral and musculoskeletal science, to present their latest research and collaborate on new opportunities to increase the testing, diagnosis and treatment options for osteoporosis and other bone diseases.

The meeting will feature recommendations to tackle the public health crisis of osteoporosis; the impact of exercise on bone mass in men; the safety of Burosomab in children and adolescents, research and guidelines to help reduce secondary fractures. Learn more about these highlights of the ASBMR 2018 Annual Meeting with specific research studies featured below.

WHAT: American Society for Bone and Mineral Research (ASBMR) 2018 Annual Meeting

WHEN: September 28 - October 1, 2018 (Friday to Monday)

WHERE: Palais des congress de Montréal, Montréal, Québec, Canada

RSVP: For more information and to register for press credentials, please contact Amanda Darvill at

Selected Highlights of the ASBMR Meeting

For a complete program, please visit Full abstracts are available to all registered media or upon request. For more media information and registration details, please go to or contact Amanda Darvill at

Please note that all abstracts are embargoed until one hour after the presentation times noted below.

  • Plenary lectures cover building bone and rare skeletal diseases

      o Gerald D. Aurbach Lecture - Building Bone by Targeting the Schnurri3 Pathway
      Laurie Glimcher, MD, Dana-Farber Cancer Institute, United States
      Friday, September 28, 08:30 am - 9:30 am

      o Louis V. Avioli Lecture - From Rare Skeletal Diseases to Genetic Determinants of Skeletal Homeostasis
      Brendan Lee, MD, PhD, Baylor College of Medicine, United States
      Saturday, September 29, 08:30 am - 9:30 am

  • Release of new recommendations to prevent secondary fractures: More than 40 bone health, health care professional and patient advocacy organizations are signing on to clinical recommendations to prevent secondary fractures and help address the public health crisis in the treatment of osteoporosis.

      o ASBMR-IOF-FFN Joint Session: Closing the Treatment Gap, Saturday,
      September 29, 11:00 am - 12:00 pm

  • Osteoporosis drug holidays are beneficial: Researchers will discuss the latest findings from a study showing the benefits of patients taking a bisphosphonate "drug holiday" in reducing the risk of atypical femur fractures (AFF).

      o The Impact of Osteoporotic (Bisphosphonate) Drug Holidays on Fracture Rates
      (Presentation #: 1006) - Friday, September 28, 1:15 pm - 1:30 pm

  • Beefing up bone mass in men: Researchers report findings from the first study document the benefit of exercise in increasing bone mass in men.

      o The Association between Objectively Measured Physical Activity and Bone
      Strength and Microarchitecture Among Older Men (Presentation #: 1118) -
      Sunday, September 30, 5:30 pm - 5:45 pm

  • Never too old to learn: Many falls in older people are the result of balance and mobility issues and land them in the hospital with fractures. Researchers will share findings from a large-scale community-based study showing programs to train on mobility and fall prevention can reduce falls and fractures.

      o Effect of Dual-Task Functional Power and Mobility Training on Falls and Physical
      Function in Older People Living in Retirement Villages: A Cluster Randomised
      Controlled Trial (Presentation #: 1060) - Saturday, September 29, 5:00 pm - 5:15 pm

  • Unexpected higher secondary fractures in men: The focus on osteoporosis and fracture risk usually zeros in on women, but researchers will share their unexpected findings from a long-term study showing men have a higher risk than women of subsequent fractures within the first year of a first fracture. While risk of secondary fracture was elevated in both men and women over the 25-year study, it was highest in the first three years following a prior fracture.

      o Changes in the Risk of Subsequent Major Osteoporotic Fractures over Time in
      Men and Women: A Population-Based Observational Study with 25-year Follow
      Up (Presentation #: 1038) - Saturday, September 29, 10:00 am - 10:15 am

  • Bone mineral density meeting the mark?: A new study provides solid evidence that bone mineral density (BMD) could meet one of the two FDA requirements for approval of surrogate markers for fracture risk, which will help clinicians select better agents for treatment.

      o Change in BMD as a Surrogate for Fracture Risk Reduction in Osteoporosis
      Trials: Results from Pooled, Individual-level Patient Data from the FNIH Bone
      Quality Project (Presentation #: 1070) - Sunday, September 30, 9:45 am - 10:00 am

  • Elevated hip fracture risk with type-2 diabetes: Researchers will present their findings that patients with type-2 diabetes who have hip replacements are prone to fractures even when their bone mineral density (BMD) is normal.

      o Advanced Glycation End Product Content is Increased in Cortical Bone of the
      Femoral Neck in Men with Type 2 Diabetes Mellitus (Presentation #: 1039) -
      Saturday, September 29, 10:15 am - 10:30 am

  • Sarcopenia predicts fracture risk: A new study provides a clearer definition of sarcopenia as a predictor of fractures risk.

      o Definitions of Sarcopenia as Predictors of Fracture Risk Independent of FRAX,
      Falls and BMD: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS)
      Study (Presentation #: 1040) - Saturday, September 29, 10:30 am - 10:45 am

  • Burosumab safety: Burosumab has recently been approved by the FDA for treatment of X-linked Hypophosphatemia (XLH) and researchers will present their findings on two studies that show it's effective and safe for children and early adolescents.

      o Sustained Efficacy and Safety of Burosumab, an Anti-FGF23 Monoclonal
      Antibody, for 88 Weeks in Children and Early Adolescents with X-Linked
      Hypophosphatemia (XLH) (Presentation #: FRI-0353/SAT-0353) - Friday,
      September 28, 5:00 pm - 7:00 pm

      o Efficacy and Safety of Burosumab, a Fully Human Anti-FGF23 Monoclonal
      Antibody, for Children 1-4 Years Old with X-linked Hypophosphatemia (XLH)
      (Presentation #: 1154) - Monday, October 1, 10:00 am - 10:15 am


The American Society for Bone and Mineral Research (ASBMR) is the leading professional, scientific and medical society established to bring together clinical and experimental scientists involved in the study of bone, mineral and musculoskeletal research. ASBMR encourages and promotes the study of this expanding field through annual scientific meetings, an official journal (Journal of Bone and Mineral Research®), the Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism, advocacy and interaction with government agencies and related societies. To learn more about upcoming meetings and publications, please visit

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.